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Background: The drug ketamine is frequently abused for recreational use in Asia, 
but few studies in humans have focused on the effects of ketamine exposure during 
pregnancy on the health of neonates. Here, we report a neonate whose mother was 
suspected of ketamine abuse during pregnancy. The case was confirmed by testing 
hair samples of the neonate.
Methods: Hair samples of the neonate were taken on the first day of referral. 
Levels of common drugs of abuse in Asia were measured in the hair sample by gas 
chromatography-mass spectrometry using our previously reported method with 
modifications. This method was developed and validated to simultaneously quan-
tify levels of amphetamine, ketamine and opiate in human hair.
Results: The neonate was a female baby, born full term, with a low birth weight of 
2250 g. Very high levels of ketamine were detected in the neonate’s hair, even 
though the mother stated that she had stopped abusing ketamine during the early 
stage of pregnancy. The neonate suffered from general hypotonia; moderate cere-
bral dysfunction was found by electroencephalography. Fortunately, her hypotonia 
improved gradually within 21 days.
Conclusion: This is the first report of ketamine exposure during late pregnancy detected 
by hair testing. We noted several clinical features in this case, including the infant 
being small for gestational age, intrauterine growth retardation, remarkable hypo-
tonia, and poor reflex responses. Although the mother denied the use of ketamine 
during the late stage of her pregnancy, significant amount of ketamine and norket-
amine was still found in hair samples (only 2 cm long and 25 mg) from the infant.
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1.  Introduction
Ketamine [2-(o-chlorophenyl)-2-(methylamino)-
cyclohexanone or K], an anesthetic primarily used 
in animals, was initially commercialized by Parke, 
Davis and Company in 1962 to replace phencyclidine 
and provide a safer anesthetic alternative which 
avoided hallucinations, neurotoxicity and seizures.1,2 
In terms of its pharmacology, ketamine is an N-methyl 
D-aspartete (NMDA) receptor antagonist, but at high 
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and full anesthetic doses, it also binds to opioid μ 
and σ receptors.2,3 One of the many “club” recrea-
tional drugs, ketamine is classified as a schedule III 
drug in Taiwan’s Drugs Hazard Control Act introduced 
in 1997. It has become one of the most popular 
recreational drugs abused by teenagers and young 
adults in rave subcultures in Taiwan.4 A comparison 
study with a parallel-group design that included 
volunteer participants showed that acute exposure 
to ketamine causes a broad spectrum of cognitive 
impairments, remarkable dissociative effects and 
schizotypal symptomatology. Moreover, the disso-
ciated effects and schizotypal symptomatology have 
been reported to last for at least 3 days. In addi-
tion, persisting impairments of semantic memory 
have been reported to exist among users 3 days after 
administration.5
Ketamine has been found to induce acute patho-
morphological changes in specific brain neurons. It 
also induces neuronal brain apoptosis and disrupts 
spontaneous activities and learning processes in 
animal studies.6 In vitro, chronic exposure to low and 
subanesthetic doses of ketamine, while not affect-
ing survival of neural cells, could still impair neu-
ronal morphology and lead to neural dysfunctions.7 
Ketamine-induced NMDA receptor hypofunction is 
associated with early-occurring memory impair-
ments followed by specific schizophrenia-like symp-
toms in humans.8 However, ketamine was reported to 
decrease “behavioral despair” in the forced swim 
test, a widely used animal model of antidepressant 
drug action. Intriguingly, it also produced anxiolytic-
like effects at lower doses, without affecting general 
locomotion measures. In another neurophysiological 
model of anxiolytic drug action, ketamine reduced 
the frequency of reticular-activated ϑ oscillations 
in the hippocampus.9
There is scarce research on the influence of 
ketamine exposure during pregnancy on the health 
of the nervous system in neonates. Most of the re-
lated studies were performed in animals. Of note, 
local cerebral glucose utilization was found to be 
impaired in fetal sheep.10 Meanwhile, taste recog-
nition memory response and taste-mediated condi-
tioned motor response were reported to be weakened 
or even blocked in rats exposed to ketamine in 
utero.11,12 It has been shown that ketamine admin-
istered to immature rodents triggered widespread 
apoptotic neurodegeneration throughout the de-
veloping brain during the period of synaptogenesis, 
which corresponds to the sixth month of gestation 
to several years after birth in humans. Thus neu-
rons of an immature central nervous system are prone 
to commit suicide if exposed to intoxicating con-
centrations of NMDA antagonists.13,14 Consequently, 
to provide greater insight into the effects of keta-
mine abuse during pregnancy, there is a need for 
more research in humans in various settings. Here, we 
report an infant whose mother stated that she stopped 
the recreational use of ketamine during the early 
stage of her pregnancy. However, we identified ket-
amine exposure in the neonate’s hair after birth. 
We suspect that the mother was still exposed to 
ketamine as late as 2 months before delivery.
2.  Materials and Methods
2.1.  Case presentation
The case is a full-term female infant, born to a 
30-year-old mother at the gestational age of 38+6 
weeks via cesarean section because of breech pres-
entation. Apgar scores were 8 at 1 minute and 9 at 
5 minutes after birth. The infant’s birth weight was 
2250 g (< 3rd percentile), body length was 47 cm (10th 
percentile), and head circumference was 33 cm (3rd 
percentile), with a ponderal index of 2.16%. The 
mother did not undergo any prenatal examination 
until 29 weeks of gestation. In addition, she con-
tinued smoking an average of five cigarettes per 
day during pregnancy. She declared that she had quit 
recreational ketamine use during the first term of 
her pregnancy (at around 8 weeks of gestation).
The infant was admitted into our neonatal in-
tensive care unit immediately after her birth through 
referral from primary medical care because of gen-
eral hypotonia. Hypotonia was predominant. Other 
general physical findings of this newborn were 
unremarkable. She also had primitive reflex. Elec-
troencephalography revealed moderate cerebral dys-
function. Her auditory brainstem response testing 
was normal. Brain ultrasonography displayed a nor-
mal brain anatomical structure. Heart, liver and 
spleen ultrasonography were also normal. Her vital 
signs were stable from the first day of admission. 
Blood culture, cerebral spinal fluid culture, toxoplas-
mosis, rubella, cytomegalovirus and herpes simplex 
survey findings were unremarkable. Chromosome 
analysis showed 46, XX. She started to receive oral 
feeding gradually at 7 days old, and her hypotonia 
improved progressively, within 21 days.
2.2.  Methods
Hair samples of the neonate were taken on the 
first day of referral. Hair was cut with the length 
of 1−2 centimeters from sites behind the ears and 
on occipital bone across an area of approximately 
5 cm2. Levels of common drugs of abuse in Asia were 
then measured in the hair by gas chromatography-
mass spectrometry (GC-MS) using our previously re-
ported method.15 A simultaneous assay was developed 
and validated with some modifications. This method 
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can simultaneously quantify amphetamines (amphet-
amine, methamphetamine, 3,4-methylenedioxyam-
phetamine, 3,4-methylenedioxy meth amphetamine, 
and 3,4-methylenedioxyethylamphetamine), keta-
mine (ketamine, norketamine), and opiates (mor-
phine, codeine and 6-acetylmorphine) in human hair.
In brief, hair samples (25 mg) were washed, cut 
and incubated overnight at 25ºC in methanol, then 
extracted by solid-phase extraction, and derivatized 
using heptafluorobutyric acid anhydride (HFBA) at 
70ºC for 30 minutes. Finally, the derivatives were 
analyzed by GC-MS in electron ionization mode with 
full scan or selected ion monitoring mode (SIM). 
GC-MS analyses were performed with an Agilent 
6890 GC interfaced to a 5973 MS in electron ion-
ization mode, and a 6890 series automatic injector 
(Agilent Technologies, Palo Alto, CA, USA). Separa-
tion was achieved with a capillary column (DB-5 MS, 
5% phenyl methyl siloxane, 30 m length × 0.25 mm 
inner diameter, 0.25 μm film thickness; Agilent 
J & W Scientific, Folsom, CA, USA) at a flow rate 
of 1 mL/min.
3.  Results
Hair testing can be used to construct a gestational 
drug exposure profile and study its potential link with 
the appearance of neonatal withdrawal syndrome. 
Although the hair of neonates is often very short, 
it still gives enough information when tested by GC-
MS. For 25 mg of hair samples, the limits of detection 
and quantification were 10 pg/mg and 20 pg/mg, 
respectively, for amphetamine, methamphetamine, 
3,4-methylenedioxyamphetamine, 3,4-methylene-
dioxy methamphetamine and 3,4-methylenedioxy-
ethylamphetamine, and 20 pg/mg and 50 pg/mg 
for ketamine, norketamine, morphine, codeine 
and 6-acetylmorphine. Calibration curves for 10 an-
alytes were established in the concentration range 
0.05−5 ng/mg with high correlation coefficients 
(r2 > 0.997) using 200 pg/mg of deuterated analogs 
of the analytes as internal standards for quantifica-
tion. All quantitative analyses were performed in 
the SIM mode, with a dwell time of 20 ms for each ion 
(Figure 1).
In this case, the neonate hair was about 2 cm long 
and it could be used to detect the drugs abused by 
the mother during the last 2−3 months of pregnancy. 
The hair testing revealed that ketamine was the only 
drug abused by the mother, and the concentra-
tions of ketamine and its metabolite norketamine 
were 141 pg/mg and 63 pg/mg of hair, respectively. 
The GC/MS SIM chromatogram of the drugs after 
derivatization with HFBA recorded norketamine-
HFBA and ketamine-HFBA at 5.19 minutes and 6.01 
minutes, respectively (Figure 2). The target ions 
monitored for ketamine and norketamine in SIM 
mode were quantization ion (m/z) 356, 360, 362 and 
366 for norketamine, norketamine-d4, ketamine and 
ketamine-d4; and qualification ions (m/z) were 340 
and 384 for norketamine, 388 for norketamine-d4, 
236 and 370 for ketamine, and 374 for ketamine-d4.
Although the mother declared that she had 
stopped recreational use of ketamine during the first 
term of her pregnancy (at around 8 weeks of ges-
tation), the results show ketamine and its metabo-
lite were present, and were authentically determined 
using deuterated analogs of the analytes as inter-
nal standards and high correlation coefficient cali-
bration curves were obtained. Thus we concluded 
that the mother had used ketamine within at least 
2 months before birth.
4.  Discussion
In recent years, ketamine has become one of the 
most commonly used recreational drugs and its 
abuse is a public health issue in Hong Kong, China, 
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Figure 1 Gas chromatography-mass spectrometry (selected ion monitoring mode) chromatogram of samples spiked 
with 5 ng/mg of the target drugs after derivatization with heptafluorobutyric acid anhydride. 1 = amphetamine; 
2 = methamphetamine; 3 = 3,4-methylenedioxyamphetamine; 4 = 3,4-methylenedioxy methamphetamine; 5 = 3,4-meth-
ylenedioxyethylamphetamine; 6 = norketamine; 7 = ketamine; 8 = morphine; 9 = codeine; 10 = 6-acetylmorphine.
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Singapore and Taiwan.16 To our knowledge, this is 
the first case report of ketamine abuse during late 
pregnancy with full clinical and laboratory evi-
dence. Although ketamine has not been reported 
as an environmental agent for neonatal malforma-
tion (unlike alcohol, hydantoin, valproate, warfa-
rin, aminopterin/methotrexate, retinoic acid, 
varicella, and hyperthermia),17 it is notable that 
the case presented as small for gestational age, 
with intrauterine growth retardation, remarkable 
hypotonia, and poor reflex responses.
Drug testing provides objective information re-
garding an individual’s use of or exposure to illicit 
drugs. Blood and urine testing are the most com-
monly used approaches, but these are only applica-
ble for exposure within the last few days. Hair differs 
from other biological specimens used for toxico-
logical analysis because of its substantially longer 
detection window (months to years), enabling ret-
rospective investigation of chronic and past con-
sumption. In addition, hair gives additional particular 
advantages; it can be easily obtained, it is difficult 
to adulterate, and it can be stored and transported 
without specific precautions because of its stability. 
Moreover, segmental hair analysis may help deter-
mine the time of drug exposure. Therefore, hair 
testing provides broader applications for evaluat-
ing clinical toxicology and clinical chemistry.
Epidemiologic studies have revealed that drug 
abusers frequently use multiple recreational drugs.18 
We recently developed a GC-MS hair testing 
method to simultaneously detect several common 
drugs of abuse in Asia. This simultaneous method is 
based on an isotope dilution mass spectrometry 
method that can eliminate the principal source of 
measurement bias and inaccuracy, and has been 
successfully used to assess different drug classes, 
including amphetamines, ketamine, opiates and their 
metabolites. Although liquid chromatography/tan-
dem mass spectrometry offers great potential for hair 
testing, GC-MS is less expensive and easier to op-
erate, and is thus often used to test for drug abuse.
Therefore, it was confirmed that this case was 
only exposed to a single recreational drug, ketamine, 
during pregnancy. Although urine is the most com-
monly used sample to detect ketamine exposure—
because of the convenience of collection—the half-life 
of ketamine in urine is only 2−3 hours.19 Thus the 
pharmacokinetics make it difficult to detect the rec-
reational use of ketamine during pregnancy. Instead, 
as reported in this study, we can infer the duration 
from the last use of ketamine based on the distance 
of the hair sample to skin. Since the rate of hair 
growth differs between people (usually 0.96−1.38 cm 
per month),20 we used the average rate of 1.2 cm 
per month to estimate the last instance of ketamine 
exposure of the mother and detected ketamine and 
norketamine at concentrations of 141 pg/mg and 
63 pg/mg hair, respectively. Thus we concluded 
that the mother had used ketamine within at least 2 
months before birth. Infants with intrauterine meth-
amphetamine exposure often present with neurobe-
havioral symptoms of decreased arousal, increased 
stress, and poor quality of movement, or even ab-
normalities of brain structure,21 whereas the clinical 
expressions of our case differed from these. Ac-
cordingly, the case reported here provides a prac-
tical demonstration for clinical practice.
Gaillard and Pepin22 reported that the amount of 
norketamine was 7−12% of that of ketamine, based 
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Figure 2 Gas chromatography-mass spectrometry (selected ion monitoring mode) chromatogram of a neonatal hair 
sample with ketamine (K) and norketamine (NK), and K-d4 and NK-d4 as internal standards.
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on their analysis of hair segments from a deceased 
woman.22 Leong et al16 also reported the ratio of 
norketamine to ketamine in hair segments (84 out 
of 91 hair segments) ranged from 0.05 to 0.84, 
with a mean of 0.33. In our case, the ratio was 
within these ranges, but higher than the mean. 
This finding could be because the body composi-
tion of women during pregnancy includes greater 
fat content. Unfor tunately, in the present study, 
because of the small number of samples, which did 
not allow for statistical analysis, the relationship 
between hair concentrations or the appearance in 
urine or blood samples, the severity of neonatal 
withdrawal syndrome could not be established.
Based on studies of humans and animal models, it 
is necessary to continue to follow up cases ex-
posed to ketamine in utero, focusing on brain de-
velopment, recognition, and learning,6 specifically 
for cognitive impairments, dissociative effects and 
schizotypal symptomatology,5 motor responses,23 
and memory impairments.8 The process of laboratory 
examination for detecting ketamine exposure level 
in hair is well established for neonates, and is even 
more feasible and precise than blood and urine 
samples for long-term exposures.15
With a broader view in public health, the con-
sequence of ketamine abuse during pregnancy, for 
instance, intimate partner violence toward women 
with substance abuse during pregnancy has gradu-
ally become increasingly important in psychology and 
sociology.24 Thus it is critical to characterize sub-
stance abusing pregnant women to identify vulnera-
ble groups and their demographic and psychosocial 
characteristics, and provide them with appropriate 
medical care.25 In addition, parental substance abuse 
is a major risk factor placing their children at higher 
risk of substance abuse later in life. Children of 
addicted parents are at greater risk of later dysfunc-
tional behaviors and need assistance to help prevent 
intergenerational transmission of drug abuse.26
5.  Conclusions
In conclusion, ketamine is a drug that is widely used 
as an anesthetic. Most clinical reports have fo-
cused on its use in cesarean or pediatric anesthesia.27 
However, ketamine has now become one of the 
most commonly abused recreational drugs worldwide 
making it an emerging topic of clinical interest for 
pediatricians and neonatologists.28 Unfortunately 
in the present study, the limited amount of samples 
did not allow for segmental analysis, the exact 
time and frequency of abuse could not be estab-
lished. However, results obtained with neonatal hair 
show that it is possible to confirm fetal drug exposure 
and corresponding it to the appearance of neonatal 
withdrawal syndrome. We believe the use of hair for 
drug testing will grow because of its ability to detect 
maternal drug use, evaluate drug exposure during 
gestation, and aid in the assessment of neonatal 
withdrawal syndrome. Further studies, including 
clinical observations of new cases and long-term 
follow-up for neurobehavioral developments, are 
needed to expand our knowledge on this issue.
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